Views
3 years ago

Entry Inhibitors Non-Nucleoside Reverse ... - myCME.com

Entry Inhibitors Non-Nucleoside Reverse ... - myCME.com

Entry Inhibitors Non-Nucleoside Reverse ... -

Updated March 2008 Northwest AIDS Education and Training Center University of Washington Produced by: Bradley Kosel, PharmD Robert Loeffelbein, PharmD David Spach, MD HIV Entry Inhibitors Non-Nucleoside RTI Integrase Inhibitors Nucleus CCR5 CD4 genomic RNA HIV HIV RNA CXCR4 HIV DNA mRNA Myr Host Cell Gag Protease Inhibitors Gag-Pol Nucleoside RTI For specific and detailed information regarding dosing recommendations, drug-drug interactions and adverse effects, see the guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents at http://aidsinfo.nih.gov Drug Name Pill Dose Adverse Effects Enfuvirtide (ENV) Fuzeon® Maraviroc (MVC) Selzentry® 90 mg/ml 150 mg 300 mg Entry Inhibitors Administered dose: 90 mg/mL subcutaneously (SQ) 2 times a day (108 mg vial diluted with 1.1 mL sterile water) • Store at controlled room temperature 1 x 300 mg tablet 2 times a day (With NRTIs, tipranavir/ritonavir, nevirapine, and weak CYP3A inhibitors or CYP3A inducers) 1 x 150 mg tablet 2 times a day (When given with strong CYP3A inhibitors with or without CYP3A inducers) 2 x 300 mg tablet 2 times a day (With CYP3A inducers including efa- Injection site reaction: pain/discomfort, induration, erythema, nodule Other: diarrhea, nausea, vomiting Fatigue, Insomnia Liver toxicity, cough, fever, upper respiratory infection, rash, musculoskeletal symptoms, stomach pain, dizziness Other: Use with caution in those with liver disease or at risk for cardiovascular events Delavirdine (DLV) Rescriptor® Efavirenz (EFV) Sustiva® Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 200 mg 200 mg 600 mg 2 x 200 mg tablets 3 times a day • May be taken with or without food 1 x 600 mg tablet once daily at bedtime 3 x 200 mg capsules once daily at bedtime • Empty stomach recommended Rash, headache, altered liver function Rash, altered liver function, dizziness, insomnia, impaired concentration, drowsiness Etravirine (ETR) Intelence® 100 mg 2 x 100 mg tablet 2 times a day • Take with food Nausea, headache, rash, Stevens-Johnson syndrome, hypersensitivity reaction, erythema Nevirapine (NVP) Viramune® 200 mg 1 x 200 mg tablet 2 times a day (start with 200 mg tablet once daily x 14 days) • May be taken with or without food Rash, headache, altered liver function www.northwestaetc.org www.hivwebstudy.org

Influence of non-nucleoside reverse transcriptase inhibitors
Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase ...
Non-nucleoside reverse transcriptase inhibitors of HIV -1
Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on ...
Binding of the Second Generation Non-nucleoside Inhibitor S-1153 ...
atural and synthetic HIV-1 non-nucleoside reverse transcriptase ...
HIV-Resistance to Viral Entry Inhibitors - retic-ris
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide ...
Entry inhibitors show promise as drugs with new MOA for treatment
Peptide Inhibitors of Flavivirus Entry Derived from the E Protein Stem †
The Structure of an HIV-1 Specific Cell Entry Inhibitor in Complex ...
Human Immunodeficiency Virus (HIV) Entry Inhibitors ... - Hem-aids.ru
A target site for template-based design of measles virus entry inhibitors